# PROOF 301 (NCT03773302)

> Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

No report yet. It can be ordered.

- Drugs tested: infigratinib
- Indication: first-line advanced cholangiocarcinoma with FGFR2 gene fusions/translocations

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03773302
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: QED Therapeutics, a BridgeBio company
- Conditions: Advanced Cholangiocarcinoma; FGFR2 Gene Mutation
- Interventions: BGJ398; Gemcitabine; Cisplatin
- Enrollment: 48
- Primary outcome: Progression-free Survival (Central Imaging Assessment)

## Indexed commentary on PROOF 301 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 7

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=proof-301-nct03773302